CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup

Angela Bowman; Hani Gabra; Simon P Langdon; Alastair Lessells; Moira Stewart; Ann Young; John F Smyth

CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup

Angela Bowman, Hani Gabra, Simon P Langdon, Alastair Lessells, Moira Stewart, Ann Young, John F Smyth

Deanery of Molecular, Genetic and Population Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

This study was an open-label Phase II trial of the aromatase inhibitor letrozole (Femara) in patients with relapsed ovarian cancer with evaluation of possible biological markers for response.

Original language	English
Pages (from-to)	2233-9
Number of pages	7
Journal	Clinical Cancer Research
Volume	8
Issue number	7
Publication status	Published - Jul 2002

Keywords / Materials (for Non-textual outputs)

Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Aromatase Inhibitors
CA-125 Antigen
Disease Progression
Enzyme Inhibitors
Female
Humans
Immunoenzyme Techniques
Middle Aged
Nitriles
Ovarian Neoplasms
Receptor, Epidermal Growth Factor
Receptor, erbB-2
Receptors, Estrogen
Receptors, Progesterone
Triazoles

Cite this

@article{30d3ffcd0dac411e9b0a78dbf8bf37e1,

title = "CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup",

abstract = "This study was an open-label Phase II trial of the aromatase inhibitor letrozole (Femara) in patients with relapsed ovarian cancer with evaluation of possible biological markers for response.",

keywords = "Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Aromatase Inhibitors, CA-125 Antigen, Disease Progression, Enzyme Inhibitors, Female, Humans, Immunoenzyme Techniques, Middle Aged, Nitriles, Ovarian Neoplasms, Receptor, Epidermal Growth Factor, Receptor, erbB-2, Receptors, Estrogen, Receptors, Progesterone, Triazoles",

author = "Angela Bowman and Hani Gabra and Langdon, {Simon P} and Alastair Lessells and Moira Stewart and Ann Young and Smyth, {John F}",

year = "2002",

month = jul,

language = "English",

volume = "8",

pages = "2233--9",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

TY - JOUR

T1 - CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer

T2 - identification of an endocrine-sensitive subgroup

AU - Bowman, Angela

AU - Gabra, Hani

AU - Langdon, Simon P

AU - Lessells, Alastair

AU - Stewart, Moira

AU - Young, Ann

AU - Smyth, John F

PY - 2002/7

Y1 - 2002/7

N2 - This study was an open-label Phase II trial of the aromatase inhibitor letrozole (Femara) in patients with relapsed ovarian cancer with evaluation of possible biological markers for response.

AB - This study was an open-label Phase II trial of the aromatase inhibitor letrozole (Femara) in patients with relapsed ovarian cancer with evaluation of possible biological markers for response.

KW - Administration, Oral

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents

KW - Aromatase Inhibitors

KW - CA-125 Antigen

KW - Disease Progression

KW - Enzyme Inhibitors

KW - Female

KW - Humans

KW - Immunoenzyme Techniques

KW - Middle Aged

KW - Nitriles

KW - Ovarian Neoplasms

KW - Receptor, Epidermal Growth Factor

KW - Receptor, erbB-2

KW - Receptors, Estrogen

KW - Receptors, Progesterone

KW - Triazoles

M3 - Article

C2 - 12114425

SN - 1078-0432

VL - 8

SP - 2233

EP - 2239

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 7

ER -

CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Fingerprint

Cite this